Skip to main content

Belite Bio, Inc 6-K, filed Nov 12, 2026

Belite Bio, Inc (BLTE)

6-K 2026-11-12 For: 2026-11-12
View Original
Added on November 13, 2026

About this 6-K

Belite Bio, Inc filed this 6-K on November 12, 2026.

Belite Bio said FDA will not convene an advisory committee for tinlarebant’s STGD1 NDA, with a PDUFA target action date of February 12, 2027. It reported a $30.3 million third-quarter net loss and $271.3 million cash and equivalents as of September 30, 2026. AI summary